Aprogen Pharmaceuticals Inc (003060) - Total Liabilities
Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) has total liabilities worth ₩288.27 Billion KRW (≈ $195.35 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Aprogen Pharmaceuticals Inc generate cash to assess how effectively this company generates cash.
Aprogen Pharmaceuticals Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check 003060 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Aprogen Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aprogen Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
C&C Group PLC
F:GCC
|
Germany | €787.20 Million |
|
Titan International Inc
NYSE:TWI
|
USA | $1.15 Billion |
|
Jilin Jinguan Electric Co Ltd Class A
SHE:300510
|
China | CN¥881.84 Million |
|
GHCL Limited
NSE:GHCL
|
India | Rs6.36 Billion |
|
ForFarmers NV
AS:FFARM
|
Netherlands | €643.10 Million |
|
Jereissati Participações S.A.
SA:IGTI3
|
Brazil | R$4.79 Billion |
|
Youngy Health Co Ltd
SHE:300247
|
China | CN¥254.09 Million |
|
Lutian Machinery Co Ltd
SHG:605259
|
China | CN¥702.28 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Aprogen Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Aprogen Pharmaceuticals Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aprogen Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aprogen Pharmaceuticals Inc (2009–2024)
The table below shows the annual total liabilities of Aprogen Pharmaceuticals Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩212.29 Billion ≈ $143.87 Million |
-3.81% |
| 2023-12-31 | ₩220.71 Billion ≈ $149.57 Million |
+27.04% |
| 2022-12-31 | ₩173.73 Billion ≈ $117.73 Million |
+896.14% |
| 2021-12-31 | ₩17.44 Billion ≈ $11.82 Million |
+2.87% |
| 2020-12-31 | ₩16.95 Billion ≈ $11.49 Million |
-3.93% |
| 2019-12-31 | ₩17.65 Billion ≈ $11.96 Million |
-73.49% |
| 2018-12-31 | ₩66.55 Billion ≈ $45.10 Million |
-17.24% |
| 2017-12-31 | ₩80.41 Billion ≈ $54.49 Million |
+59.01% |
| 2016-12-31 | ₩50.57 Billion ≈ $34.27 Million |
+189.37% |
| 2015-12-31 | ₩17.48 Billion ≈ $11.84 Million |
-23.06% |
| 2014-12-31 | ₩22.71 Billion ≈ $15.39 Million |
+4.62% |
| 2013-12-31 | ₩21.71 Billion ≈ $14.71 Million |
-11.65% |
| 2012-12-31 | ₩24.58 Billion ≈ $16.65 Million |
-42.64% |
| 2011-12-31 | ₩42.85 Billion ≈ $29.04 Million |
+19.37% |
| 2010-12-31 | ₩35.89 Billion ≈ $24.32 Million |
+36.66% |
| 2010-09-30 | ₩26.26 Billion ≈ $17.80 Million |
-22.50% |
| 2009-12-31 | ₩33.89 Billion ≈ $22.97 Million |
-- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.